STOCK TITAN

[SCHEDULE 13G] Enveric Biosciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Enveric Biosciences, Inc. (ENVB) Schedule 13G filed by Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC reports shared beneficial ownership of warrants and shares following a September 17, 2025 letter agreement with the issuer. After that transaction the Reporting Persons may be deemed to beneficially own 266,668 shares each held by Intracoastal (approximately 5.2% of outstanding common stock based on 5,079,612 shares) if certain warrants were exercisable, but as of the close of business on September 24, 2025 each Reporting Person may be deemed to own 19,333 shares (approximately 0.4%) issuable upon exercise of Intracoastal Warrant 3. Intracoastal Warrant 1 and 2 are not exercisable pending shareholder approval and all three warrants contain blocker provisions limiting exercises above 4.99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G presentata da Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC segnala una proprietà beneficiaria condivisa su warrant e azioni a seguito di un accordo con l’emittente datato 17 settembre 2025. Dopo tale operazione i Reporting Persons potrebbero essere considerati titolari beneficiari di 266.668 azioni ciascuna detenute da Intracoastal (circa 5,2% del capitale azionario ordinario in circolazione, basato su 5.079.612 azioni) se alcuni warrant fossero esercitabili; ma al termine della giornata lavorativa del 24 settembre 2025 ciascun Reporting Person potrebbe essere considerato titolare di 19.333 azioni (circa 0,4%) che verrebbero emesse all’esercizio del Warrant 3 di Intracoastal. Il Warrant 1 e 2 di Intracoastal non sono esercitabili in attesa dell’approvazione degli azionisti e tutti e tre i warrant contengono clausole di blocco che limitano gli esercizi oltre il 4,99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G presentada por Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC informa de una propiedad beneficiosa compartida de warrants y acciones tras un acuerdo por escrito con el emisor fechado el 17 de septiembre de 2025. Tras dicha operación, las Personas Reportantes podrían considerarse con la propiedad beneficiosa de 266.668 acciones que cada una posee Intracoastal (aproximadamente el 5,2% del capital social en circulación basado en 5.079.612 acciones) si ciertos warrants fueran ejercitables; pero al cierre de negocios del 24 de septiembre de 2025 cada Persona Reportante podría considerarse propietaria de 19.333 acciones (aproximadamente el 0,4%) emitibles al ejercicio del Warrant 3 de Intracoastal. Los Warrant 1 y 2 de Intracoastal no son ejercitables hasta la aprobación de los accionistas y los tres warrants contienen cláusulas de bloqueo que limitan los ejercicios por encima del 4,99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G는 Mitchell P. Kopin, Daniel B. Asher 및 Intracoastal Capital LLC가 발행사와의 2025년 9월 17일 서면 합의에 따라 취득한 워런트와 주식의 공동 이익 소유를 보고합니다. 그 거래 이후 보고자들은 Intracoastal가 보유한 각 266,668주를 효과적으로 유익하게 소유할 수 있는 것으로 간주될 수 있다 (발행주식 5,079,612주 기준 약 5.2%) 워런트의 행사 가능 여부에 따라 다르며, 2025년 9월 24일 영업 마감 시각에는 각 보고인이 워런트 3의 행사에 의해 발행될 19,333주를 소유하는 것으로 간주될 수 있습니다(약 0.4%). Intracoastal 워런트 1 및 2는 주주 승인 대기 중 행사 불가이며, 세 워런트 모두 4.99%를 초과하는 행사를 제한하는 차단 조항을 포함합니다.

Enveric Biosciences, Inc. (ENVB) Schedule 13G déposée par Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC signale une propriété bénéficiaire commune de warrants et d’actions à la suite d’un accord écrit avec l’émetteur daté du 17 septembre 2025. Après cette opération, les personnes déclarantes pourraient être réputées détenir 266 668 actions chacune détenues par Intracoastal (environ 5,2% des actions ordinaires en circulation basées sur 5 079 612 actions) si certains warrants étaient exerçables; mais à la clôture des activités le 24 septembre 2025, chaque personne déclarant pourrait être réputée détenir 19 333 actions (environ 0,4%) pouvant être émises lors de l’exercice du warrant 3 d’Intracoastal. Les warrants 1 et 2 d’Intracoastal ne sont pas exerçables en attendant l’approbation des actionnaires et les trois warrants contiennent des dispositions bloquant les exercices au-delà de 4,99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G, eingereicht von Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC, berichtet über gemeinschaftlich beherrschte Eigentumsverhältnisse an Warrants und Aktien nach einer am 17. September 2025 getroffenen Briefvereinbarung mit dem Emittenten.Nach dieser Transaktion könnten die Offenlegungs-Personen jeweils als Eigentümer von 266.668 Aktien gelten, die von Intracoastal gehalten werden (ungefähr 5,2% des ausgegebenen Stammkapitals basierend auf 5.079.612 Aktien), falls bestimmte Warrants ausübbar sind; zum Geschäftsschluss am 24. September 2025 könnten jedoch jeweils 19.333 Aktien (ca. 0,4%) als durch Ausübung des Intracoastal-Warrants 3 ausübbar gelten. Intracoastal Warrants 1 und 2 sind bis zur Hauptaktionärsfreigabe nicht ausübbar, und alle drei Warrants enthalten Sperrbefugnisse, die Ausübungen über 4,99% hinaus begrenzen.

Enveric Biosciences, Inc. (ENVB) Schedule 13G المقدم من ميتشل P. كوبين، ودانيال ب. آشِر، وIntracoastal Capital LLC يسجّل ملكية فائدة مشتركة في الضمانات والأسهم عقب اتفاق مكتوب مع المُصدر المؤرّخ في 17 سبتمبر 2025. بعد تلك الصفقة، قد تعتبر أطراف الإبلاغ مالكة فاعلة لــ 266,668 سهمًا لكل واحد من Intracoastal (حوالي 5.2% من إجمالي الأسهم العادية القائمة بناءً على 5,079,612 سهمًا) إذا كانت بعض الضمانات قابلة للمطالبة بها، لكن حتى نهاية يوم العمل في 24 سبتمبر 2025 قد تعتبر كل جهة من جهات الإبلاغ مالكة لـ 19,333 سهمًا (حوالي 0.4%) يمكن Exercising من Warrants Intracoastal 3. Warrants Intracoastal 1 و2 غير قابلة للمطالبة حتى موافقة المساهمين، وجميع الضمانات الثلاث تحتوي بنود حَظر تحد من التمارين فوق 4.99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G 由 Mitchell P. Kopin、Daniel B. Asher 和 Intracoastal Capital LLC 提交,报告在发行人于 2025 年 9 月 17 日签署的书面协议后对认股权证和股份的共同受益所有权。交易后,报告人应被认定为各自持有 Intracoastal 的 266,668 股(基于流通在外的 5,079,612 股约占 5.2%),若某些认股权证可被执行;但截至 2025 年 9 月 24 日营业结束时,每位报告人 可被认定拥有 19,333 股(约 0.4%),可通过执行 Intracoastal 第 3 号认股权证来取得。Intracoastal 第 1 号和第 2 号认股权证在股东批准前不可行使,三份认股权证都包含阻断条款,限制行使比例超过 4.99%。

Positive
  • Transparent disclosure of warrant holdings, exercisability conditions and blocker provisions
  • Clear certification that holdings are not intended to change or influence issuer control
  • Shared voting and dispositive power limited to 19,333 shares (0.4%), indicating no current large stake
Negative
  • Potential for future dilution or increased ownership exists through warrants (266,668 each) if shareholder approvals occur
  • Complex exercisability conditions and blocker provisions may create uncertainty about timing and actual ownership impact

Insights

TL;DR: Reporting persons hold limited current voting/dispositive power via warrants; potential ownership increases are blocked until shareholder approvals.

The filing shows each reporting person has shared voting and dispositive power over 19,333 shares (0 votes solely). Materiality hinges on exercisability: two larger warrants (266,668 shares each) are not exercisable until stockholder approval and include 4.99% blocker provisions, which prevents automatic concentration above that threshold. Current reported beneficial ownership is 0.4% of the post-transaction class; without blockers and with exercisability the stake could be reported as materially larger (~5.2% per intracoastal holdings), but the filing explicitly excludes those shares until conditions are met. The certification affirms the holdings are not intended to influence control.

TL;DR: Governance impact appears limited now; blocker provisions and approval conditions constrain near-term control effects.

The Schedule 13G discloses that the reporting group shares power over warrants and a modest number of shares, and it repeatedly documents exercise restrictions and blocker provisions that cap ownership at 4.99% absent shareholder actions. Signatures from the individuals and Intracoastal certify non-control intent. For governance purposes, the filing signals non-activist, passive intent under Schedule 13G standards while preserving potential future economic exposure if warrants become exercisable following shareholder approvals.

Enveric Biosciences, Inc. (ENVB) Schedule 13G presentata da Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC segnala una proprietà beneficiaria condivisa su warrant e azioni a seguito di un accordo con l’emittente datato 17 settembre 2025. Dopo tale operazione i Reporting Persons potrebbero essere considerati titolari beneficiari di 266.668 azioni ciascuna detenute da Intracoastal (circa 5,2% del capitale azionario ordinario in circolazione, basato su 5.079.612 azioni) se alcuni warrant fossero esercitabili; ma al termine della giornata lavorativa del 24 settembre 2025 ciascun Reporting Person potrebbe essere considerato titolare di 19.333 azioni (circa 0,4%) che verrebbero emesse all’esercizio del Warrant 3 di Intracoastal. Il Warrant 1 e 2 di Intracoastal non sono esercitabili in attesa dell’approvazione degli azionisti e tutti e tre i warrant contengono clausole di blocco che limitano gli esercizi oltre il 4,99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G presentada por Mitchell P. Kopin, Daniel B. Asher e Intracoastal Capital LLC informa de una propiedad beneficiosa compartida de warrants y acciones tras un acuerdo por escrito con el emisor fechado el 17 de septiembre de 2025. Tras dicha operación, las Personas Reportantes podrían considerarse con la propiedad beneficiosa de 266.668 acciones que cada una posee Intracoastal (aproximadamente el 5,2% del capital social en circulación basado en 5.079.612 acciones) si ciertos warrants fueran ejercitables; pero al cierre de negocios del 24 de septiembre de 2025 cada Persona Reportante podría considerarse propietaria de 19.333 acciones (aproximadamente el 0,4%) emitibles al ejercicio del Warrant 3 de Intracoastal. Los Warrant 1 y 2 de Intracoastal no son ejercitables hasta la aprobación de los accionistas y los tres warrants contienen cláusulas de bloqueo que limitan los ejercicios por encima del 4,99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G는 Mitchell P. Kopin, Daniel B. Asher 및 Intracoastal Capital LLC가 발행사와의 2025년 9월 17일 서면 합의에 따라 취득한 워런트와 주식의 공동 이익 소유를 보고합니다. 그 거래 이후 보고자들은 Intracoastal가 보유한 각 266,668주를 효과적으로 유익하게 소유할 수 있는 것으로 간주될 수 있다 (발행주식 5,079,612주 기준 약 5.2%) 워런트의 행사 가능 여부에 따라 다르며, 2025년 9월 24일 영업 마감 시각에는 각 보고인이 워런트 3의 행사에 의해 발행될 19,333주를 소유하는 것으로 간주될 수 있습니다(약 0.4%). Intracoastal 워런트 1 및 2는 주주 승인 대기 중 행사 불가이며, 세 워런트 모두 4.99%를 초과하는 행사를 제한하는 차단 조항을 포함합니다.

Enveric Biosciences, Inc. (ENVB) Schedule 13G déposée par Mitchell P. Kopin, Daniel B. Asher et Intracoastal Capital LLC signale une propriété bénéficiaire commune de warrants et d’actions à la suite d’un accord écrit avec l’émetteur daté du 17 septembre 2025. Après cette opération, les personnes déclarantes pourraient être réputées détenir 266 668 actions chacune détenues par Intracoastal (environ 5,2% des actions ordinaires en circulation basées sur 5 079 612 actions) si certains warrants étaient exerçables; mais à la clôture des activités le 24 septembre 2025, chaque personne déclarant pourrait être réputée détenir 19 333 actions (environ 0,4%) pouvant être émises lors de l’exercice du warrant 3 d’Intracoastal. Les warrants 1 et 2 d’Intracoastal ne sont pas exerçables en attendant l’approbation des actionnaires et les trois warrants contiennent des dispositions bloquant les exercices au-delà de 4,99%.

Enveric Biosciences, Inc. (ENVB) Schedule 13G, eingereicht von Mitchell P. Kopin, Daniel B. Asher und Intracoastal Capital LLC, berichtet über gemeinschaftlich beherrschte Eigentumsverhältnisse an Warrants und Aktien nach einer am 17. September 2025 getroffenen Briefvereinbarung mit dem Emittenten.Nach dieser Transaktion könnten die Offenlegungs-Personen jeweils als Eigentümer von 266.668 Aktien gelten, die von Intracoastal gehalten werden (ungefähr 5,2% des ausgegebenen Stammkapitals basierend auf 5.079.612 Aktien), falls bestimmte Warrants ausübbar sind; zum Geschäftsschluss am 24. September 2025 könnten jedoch jeweils 19.333 Aktien (ca. 0,4%) als durch Ausübung des Intracoastal-Warrants 3 ausübbar gelten. Intracoastal Warrants 1 und 2 sind bis zur Hauptaktionärsfreigabe nicht ausübbar, und alle drei Warrants enthalten Sperrbefugnisse, die Ausübungen über 4,99% hinaus begrenzen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Mitchell P. Kopin
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin
Date:09/24/2025
Daniel B. Asher
Signature:/s/ Daniel B. Asher
Name/Title:Daniel B. Asher
Date:09/24/2025
Intracoastal Capital LLC
Signature:/s/ Mitchell P. Kopin
Name/Title:Mitchell P. Kopin/Manager
Date:09/24/2025
Exhibit Information

Exhibit 1 - Joint Filing Agreement

FAQ

How many ENVB shares do the reporting persons currently beneficially own?

As of the close of business on September 24, 2025 each reporting person may be deemed to beneficially own 19,333 shares, representing approximately 0.4% of the outstanding common stock per the filing.

Why are larger share amounts excluded from the current ownership percentage?

The filing excludes shares issuable upon exercise of Intracoastal Warrant 1 and 2 (266,668 shares each) because those warrants are not exercisable until shareholder approval and contain 4.99% blocker provisions.

What voting power do the reporting persons have over ENVB shares?

Each reporting person reports 0 sole voting power and 19,333 shared voting power for the disclosed shares.

Do the reporting persons claim intent to influence control of ENVB?

No. The certifications state the securities were not acquired and are not held for the purpose of changing or influencing control, other than activities solely related to a nomination under specified rules.

What would ownership look like if warrants were exercisable without blockers?

The filing states that without blocker provisions and assuming exercisability of Warrant 1 and 2, each reporting person may have been deemed to beneficially own 800,004 shares in one scenario and 552,669 shares in another—figures the filing presents for exclusionary context.
Enveric Biosciences Inc

NASDAQ:ENVB

ENVB Rankings

ENVB Latest News

ENVB Latest SEC Filings

ENVB Stock Data

3.46M
3.02M
6.84%
10.2%
12.25%
Biotechnology
Pharmaceutical Preparations
Link
United States
NAPLES